Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
2022年年度审计报告
Regulatory Filings
2023-04-25 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled '北京双鹭药业股份有限公司 2022 年年度报告全文' which translates to 'Beijing SL Pharmaceutical Co., Ltd. 2022 Annual Report Full Text'. It contains detailed sections including company overview, financial data, management discussion and analysis, governance, environmental and social responsibility, important matters, shareholder information, bond information, and a full financial report. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial statements and management's discussion, which are typical components of an Annual Report. There is no indication that this is merely an announcement or a certification document. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese
2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Report Summary" of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains detailed financial data for the year 2022, including revenue, net profit, cash flow, and R&D investment. It also includes comprehensive business descriptions, product lines, market performance, shareholder information, and legal proceedings. The length of the document (12,599 characters) and the depth of financial and operational data indicate it is a substantive financial report rather than a brief announcement or presentation. The document is clearly a summary of the full annual report, which is a type of official yearly report covering company activity and full financial performance. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-04-25 Chinese
监事会决议公告
AGM Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing SL Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the 2022 fiscal year, including the 2022 Annual Report, Supervisory Board Work Report, Financial Final Accounts Report, Profit Distribution Proposal, Internal Control Evaluation Report, and the appointment of the 2023 audit firm. It also includes approval of the 2023 Q1 report and other operational matters. The document is a formal announcement of the Supervisory Board's meeting decisions and approvals, not the reports themselves. The document length is 3399 characters, which is relatively short and consistent with an announcement rather than a full report. The document states that these reports and proposals will be submitted to the 2022 Annual General Meeting for approval, indicating this is a meeting resolution announcement. Therefore, this document fits best into the category of AGM Information (AGM-R), as it contains materials and resolutions from a general meeting or supervisory board meeting related to the annual report and other corporate governance matters.
2023-04-25 Chinese
2022年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled "2022 年度社会责任报告" which translates to "2022 Annual Social Responsibility Report". It covers topics such as company basic information, shareholder and creditor rights protection, employee rights protection, supplier and customer rights protection, and environmental protection and sustainable development. The content focuses on the company's performance and initiatives related to social responsibility, including environmental, social, and governance (ESG) factors. There is no indication that this is a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or a transcript. The detailed coverage of social responsibility and ESG topics aligns with the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is Environmental & Social Information (SR).
2023-04-25 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to audit committee operations, information disclosure, insider trading controls, fundraising, related party transactions, guarantees, major investments, and other important matters. The document is issued by the company's board and dated April 24, 2023. It is a self-assessment or internal control compliance checklist rather than a financial report, earnings release, or regulatory announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of a report. It is also not a certification or legal proceeding document. Given the nature of the content focusing on internal control rules and their implementation, this fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous compliance and internal control related filings that do not fit other categories.
2023-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.